← Human Trials & Peer-Reviewed Studies
The effect of repeated administration of hexarelin, a growth hormone releasing peptide, and growth hormone releasing hormone on growth hormone responsivity
Plain-language guide to PMID 8762732 (1996): randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone).
Key Facts
- PMID
- 8762732
- Journal
- Clinical endocrinology
- Year
- 1996
- Study type
- Randomized Controlled Trial
- Authors
- Massoud AF et al. (4 authors)
- DOI
- 10.1046/j.1365-2265.1996.722543.x
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone).
Hexarelin is a synthetic six-amino-acid compound capable of releasing GH in animals and in man.
Its mechanism of action is not understood and little is known about the GH response after repeated administration.
The aim of this study was to determine the GH response to the administration of two intravenous boluses of hexarelin, growth hormone releasing hormone (GHRH) or hexarelin with GHRH.
Who Took Part
The age groups tagged for this paper are adults, men only.
How the Study Was Run
In design terms this was a randomized study.
Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.
Each study was performed on two further occasions, with a second bolus being administered 60 or 120 minutes after the first.
A control study was performed giving saline intravenously.
Studies were performed in a random order.
Serum GH was measured by radioimmunoassay.
GH secretion rates were derived from the measured serum GH concentrations using the technique of deconvolution analysis.
What Was Measured
Topics PubMed links to this paper include Drug Synergism, Growth Hormone, Growth Hormone-Releasing Hormone, Hormones, Oligopeptides, Peptide Fragments and Radioimmunoassay.
What This Means in Plain Language
The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone).
Its findings take up roughly 10 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 1996 (Clinical endocrinology), a journal based in England.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.
Our Notes on the Compounds
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
GHRH (Growth Hormone-Releasing Hormone): The 44-amino-acid hypothalamic hormone that tells the pituitary to release growth hormone; sermorelin and tesamorelin are analogs.
Hexarelin: A potent synthetic hexapeptide GH secretagogue, also studied for direct heart effects via the CD36 receptor.
Related Pages
- Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library
- GHRH (Growth Hormone-Releasing Hormone) in the library
- Hexarelin in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.